SCHEMBL960358

SCHEMBL960358

CCOc1ccc2nc(NC(=O)NS(=O)(=O)c3ccccc3C)sc2c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.66
SMN1; SMN2 Q16637 8/20 0.66
NPC1 O15118 8/20 0.66
RAB9A P51151 8/20 0.66
KMT2A Q03164 4/20 0.66
MEN1 O00255 2/20 0.66
POLB P06746 2/20 0.66
USP2 O75604 1/20 0.66
TDP1 Q9NUW8 1/20 0.66
TP53 P04637 3/20 0.61
MAPK1 P28482 3/20 0.60
GAA P10253 2/20 0.60
ALOX15 P16050 1/20 0.60
NFKB1 P19838 1/20 0.60
CASP3 P42574 1/20 0.60
NFKB2 Q00653 1/20 0.60
RELA Q04206 1/20 0.60
SENP8 Q96LD8 1/20 0.60
SENP7 Q9BQF6 1/20 0.60
SENP6 Q9GZR1 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21858365 0.83 RAB9A (0.75) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL957109 0.82 FBP1 (0.58) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL959411 0.82 ACP1 (0.65) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL6231579 0.79 MAPT (1.00) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL27093200 0.77 MAPT (0.82) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL15376318 0.77 MAPT (0.78) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL2247099 0.76 MAPT (1.00) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL27093090 0.76 NPC1 (0.80) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL9988019 0.76 NPC1 (0.67) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL6229213 0.76 SMN1; SMN2 (0.82) MAPTSMN1; SMN2NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868030-B2 FBPase inhibitors for diabetes HOFFMANN-LA ROCHE INC. (US) 2011-01-11 US claimed
EP-2032548-A1 THIAZOLE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2009-03-11 EP claimed
WO-2007137962-A1 THIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-12-06 WO claimed
US-20070281979-A1 Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents HOFFMANN-LA ROCHE INC. 2007-12-06 US claimed
US-7868030-B2 FBPase inhibitors for diabetes HOFFMANN-LA ROCHE INC. (US) 2011-01-11 US disclosed
EP-2032548-A1 THIAZOLE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2009-03-11 EP disclosed
WO-2007137962-A1 THIAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-12-06 WO disclosed
US-20070281979-A1 Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents HOFFMANN-LA ROCHE INC. 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281979-A1 Fructose-1,6-bisphosphatase (FBPase) inhibitors, such as N-[(5-bromo-1,3-thiazol-2-yl)carbamoyl]3(difluoromethoxy)benzenesulfonamide, used as antidiabetic agents FBP1, PFKFB1, PFKFB3 MAPT 3081/4885SMN1; SMN2 3284/4885NPC1 1201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.